19 completed, 3 active not recruiting, 3 terminated, 3 unknown. 29 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 29 | Completed 19, Active not recruiting 3, Terminated 3, Unknown 3, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Metal Metabolism, Inborn Errors: new trials by email Literature Review of Metal Metabolism, Inborn Errors trials Research Report on Metal Metabolism, Inborn Errors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. TETA 4HCl formulation, D-Penicillamine - Wilson's Disease | Phase 3 | Recruiting | Orphalan | 38 | 2026-09-03 | 2026-10-15 |
| Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP ALXN1850, Placebo - Hypophosphatasia | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 30 | 2024-05-14 | 2026-05-28 |
| Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa ALXN1850, asfotase alfa - Hypophosphatasia | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 43 | 2024-04-02 | 2026-05-05 |
| Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa ALXN1850, Placebo - Hypophosphatasia | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 124 | 2024-01-03 | 2026-06-22 |
| Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease ALXN1840, Standard of Care - Wilson Disease | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 40 | 2021-09-13 | 2024-10-23 |
| Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT adhesive system, fluoride varnish, flowable composite - X-linked Hypophosphatemia (XLH) | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 60 | 2021-06-01 | 2021-05-05 |
| Anti-FGF23 (Burosumab) in Adult Patients With XLH Burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Wuerzburg University Hospital | 36 | 2021-01-07 | 2023-05-03 |
| Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH Burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 35 | 2019-03-07 | 2022-05-20 |
| Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease Penicillamine (D1-W12), TETA 4HCL (W12-60), Penicillamine (W12-W60) - Wilson Disease | Phase 3 | Completed | Orphalan | 77 | 2018-09-03 | 2025-07-02 |
| Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease ALXN1840, SoC Therapy - Wilson Disease | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 214 | 2018-02-22 | 2024-06-17 |
| A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia KRN23 - X-linked Hypophosphatemic Rickets/Osteomalacia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 16 | 2017-07-06 | 2022-09-06 |
| Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH burosumab, Oral Phosphate Supplement, active vitamin D - X-Linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 61 | 2016-09-08 | 2024-08-29 |
| Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 14 | 2015-12-23 | 2024-06-18 |
| Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) burosumab, Placebo - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 134 | 2015-10-22 | 2024-06-18 |
| Lamotrigine as Treatment of Myotonia Lamotrigine, Placebo - Dystrophia Myotonica Type 1, Myotonia Congenita | Phase 3 | Completed | Grete Andersen, MD | 27 | 2013-11-01 | 2016-04-25 |
| Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®) G.S.P. Oral Solution 400 mg/ml - Galactose Single Point (GSP), Residual Liver Function | Phase 3 | Unknown | Richever Enterprise Co., Ltd. | 200 | 2013-09-09 | 2018-03-07 |
| Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia | Phase 2 / Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 69 | 2010-07-01 | 2019-03-13 |
| Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency Copper Histidine - Menkes Disease, Occipital Horn Syndrome | Phase 3 | Completed | Cyprium Therapeutics, Inc. | 93 | 2009-02-27 | 2020-11-19 |
| Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients Phlebotomy and erythrocytapheresis - Hereditary Hemochromatosis | Phase 3 | Unknown | Sanquin Research & Blood Bank Divisions | 40 | 2008-05-01 | 2013-12-04 |
| Hyper- and Hypokalemic Periodic Paralysis Study Dichlorphenamide (double-blind), Placebo (double-blind), Dichlorphenamide (open-label) - Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis | Phase 3 | Completed | University of Rochester | 71 | 2007-06-01 | 2017-06-14 |
Showing 20 of 29. Sign in to see all of them.
Familial Hypophosphatemic Rickets (8) · Hemochromatosis (6) · Hepatolenticular Degeneration (6) · Hypophosphatasia (4) · Paralysis, Hyperkalemic Periodic (3) · Hypokalemic Periodic Paralysis (2) · Myotonic Disorders (2) · Osteomalacia (2) · Rare Diseases (2) · Rickets (2) · Anemia, Sickle Cell (1) · Bone Diseases (1) · Carcinoma, Hepatocellular (1) · Fibrosis (1) · Hematologic Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (29) · Genetic Diseases, Inborn (29) · Metabolic Diseases (29) · Nutritional and Metabolic Diseases (29) · Metabolism, Inborn Errors (28) · Musculoskeletal Diseases (13) · Nervous System Diseases (11) · Bone Diseases, Metabolic (10) · Calcium Metabolism Disorders (10) · Avitaminosis (9) · Bone Diseases (9) · Deficiency Diseases (9) · Malnutrition (9) · Nutrition Disorders (9)
burosumab (6) · Phlebotomy (3) · Dichlorphenamide (2) · Penicillamine (2) · asfotase alfa (2) · tetrathiomolybdate (2) · Bloodletting (1) · Deferiprone (1) · Deferoxamine (1) · Double-Blind Method (1) · Erythrocyte Transfusion (1) · Hydroxyurea (1) · Iron Chelating Agents (1) · Lamotrigine (1) · Long Interspersed Nucleotide Elements (1)
Alexion Pharmaceuticals, Inc. (6) · Kyowa Kirin, Inc. (3) · Assistance Publique - Hôpitaux de Paris (2) · National Center for Research Resources (NCRR) (2) · Orphalan (2) · Sanquin Research & Blood Bank Divisions (2) · Cyprium Therapeutics, Inc. (1) · Grete Andersen, MD (1) · Kyowa Kirin Co., Ltd. (1) · Kyowa Kirin Pharmaceutical Development Ltd (1) · Lipomed (1) · Nobelpharma (1) · Richever Enterprise Co., Ltd. (1) · San Filippo Neri General Hospital (1) · St. Jude Children's Research Hospital (1)
United States (15) · United Kingdom (10) · France (9) · Japan (9) · Australia (7) · Canada (7) · Italy (7) · Germany (6) · South Korea (6) · Turkey (Türkiye) (6) · Poland (5) · Spain (5) · Denmark (4) · Brazil (3) · China (3)
Eva Rombout, MD (2) · Amal M El-Beshlawy, Prof. Dr. (1) · Eugene S. Swenson, M.D., Ph.D. (1) · Eugene S. Swenson, MD, PhD (1) · Francesco Equitani, M.D. (1) · George J. Brewer (1) · Grete Andersen, MD (1) · Jean-Claude Trinchet, Pr, MD, PhD (1) · Jerry R. Mendell (1) · Koudou Ishii, M.D. (1) · Lothar Seefried, MD (1) · Michael McDermott, Ph.D. (1) · Peter Kamenicky (1) · Rabi Tawil, M.D. (1)
PMID 39151033, PMID 36854566, PMID 17959863, PMID 18055982, PMID 18351337, PMID 21078496, PMID 21826782, PMID 21848963, PMID 22144108, PMID 22180427, PMID 22318199, PMID 23861242, PMID 24914136, PMID 25029424, PMID 25284616, PMID 26529632, PMID 29947083, PMID 30811537, PMID 31104833, PMID 31165191, PMID 32721016, PMID 32762706, PMID 33368569, PMID 33484279, PMID 34522876, PMID 34548383, PMID 35533340, PMID 35775373, PMID 35927518, PMID 36183738, PMID 36719566, PMID 37084401, PMID 39139457, PMID 41831608
2014 (1), 2017 (1), P50AR054086 (1), U01HL078787 (1)